Stockreport

Kineta Announces Exclusivity and Right of First Offer Agreement for its VISTA blocking antibody with TuHURA Biosciences [Yahoo! Finance]

Kineta, Inc.  (KA) 
PDF KVA12123 is currently in a Phase 1/Phase 2 Clinical Study in the United States SEATTLE, July 08, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage [Read more]